文献速递临床试验与 GCP基础与转化研究

替奈普酶桥接取栓治疗4.5至24小时缺血性卒中随机试验

Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

TNX-PLUS 多中心三期随机对照试验纳入 391 例发病 4.5 至 24 小时、近端大脑中动脉闭塞且存在可挽救脑组织的缺血性卒中患者,比较静脉替奈普酶(0.25 mg/kg,最大 25 mg)桥接血管内治疗与单纯血管内治疗。结果显示 90 天功能独立率分别为 44.2% 与 43.2%,差异无统计学意义,替奈普酶未改善临床结局。

要点

  • 晚时间窗(4.5–24 小时)近端大脑中动脉闭塞患者,替奈普酶桥接取栓未提高 90 天功能独立率。
  • 两组 90 天死亡率分别为 12.7% 与 14.2%,症状性颅内出血分别为 5.1% 与 2.6%。
  • 该试验不支持对符合影像筛选标准的晚时间窗患者常规在取栓前使用替奈普酶。

核心结论

  • 在发病 4.5 至 24 小时的近端大脑中动脉闭塞缺血性卒中患者中,静脉替奈普酶桥接血管内治疗与单纯血管内治疗相比未改善临床结局。

研究设计与样本

  • 多中心、三期、随机、开放标签、盲法终点、优效性试验,在中国 40 家中心开展。
  • 纳入 391 例成人(≥18 岁)急性缺血性卒中患者,发病 4.5 至 24 小时,MCA-M1 或近端 M2 闭塞,影像筛选显示可挽救脑组织(缺血核心体积 <70 mL,不匹配比 ≥1.8,不匹配体积 ≥15 mL)。
  • 患者按 1:1 随机分配至静脉替奈普酶(0.25 mg/kg,最大剂量 25 mg)桥接血管内治疗组(n=199)或单纯血管内治疗组(n=192),随访 90 天。

主要发现

  • 90 天内死亡率在替奈普酶桥接组为 12.7%(25/197),单纯取栓组为 14.2%(27/190)。
  • 36 小时内症状性颅内出血在替奈普酶桥接组为 5.1%(10/197),单纯取栓组为 2.6%(5/190)。

关键数值与推荐

  • 替奈普酶剂量为 0.25 mg/kg,最大剂量 25 mg,于血管内治疗前静脉给药。
  • 影像筛选标准:缺血核心体积 <70 mL,不匹配比 ≥1.8,不匹配体积 ≥15 mL。
  • 主要结局为 90 天改良 Rankin 量表评分 0–2 分(范围 0–6,评分越高残疾越重)。

临床怎么用

  • 对于发病 4.5 至 24 小时、符合影像筛选标准的近端大脑中动脉闭塞患者,取栓前常规静脉替奈普酶未显示额外获益。
  • 临床决策需结合患者个体情况、出血风险及当地诊疗规范综合判断。

局限性

  • 试验在中国 40 家中心开展,结果外推至其他人群或医疗体系时需谨慎。
  • 开放标签设计可能引入实施偏倚,尽管终点评估采用盲法。
  • 症状性颅内出血在替奈普酶桥接组数值上高于单纯取栓组,但原文未报告该比较的统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Whether intravenous tenecteplase prior to endovascular treatment (EVT) for ischemic stroke reduces disability in the late time window is unclear. OBJECTIVE: To investigate the adverse events and efficacy of tenecteplase prior to EVT in patients 4.5 to 24 hours after ischemic stroke onset due to proximal middle cerebral artery (MCA) occlusion. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, phase 3, randomized, open-label, blinded end point, superiority trial conducted at 40 centers in China. Adult (≥18 years) patients with acute ischemic stroke 4.5 to 24 hours after last known to be well due to MCA-M1 or proximal M2 occlusion with salvageable brain tissue (ischemic core volume <70 mL, mismatch ratio ≥1.8, and mismatch volume ≥15 mL) identified on computed tomography-perfusion or magnetic resonance-perfusion-diffusion imaging were enrolled from January 25, 2024, through July 21, 2025, and followed up for 90 days. Final follow-up occurred on October 14, 2025. INTERVENTIONS: Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous tenecteplase (0.25 mg/kg; maximum dose, 25 mg) before EVT (n = 199) or EVT alone (n = 192). MAIN OUTCOMES AND MEASURES: The primary outcome was functional independence, defined as a score of 0 to 2 on the modified Rankin Scale (range, 0-6, with higher scores indicating greater disability) at 90 days. Adverse events outcomes included symptomatic intracranial hemorrhage and death. RESULTS: All of the 391 patients enrolled (median age, 68 years [IQR, 59-75]; 155 [39.6%] females) completed the trial. Functional independence at 90 days occurred in 88 patients (44.2%) in the tenecteplase before EVT group and 83 patients (43.2%) in the EVT alone group (adjusted relative rate, 1.01 [95% CI, 0.83-1.24]; P = .89; risk difference, 0.99% [95% CI, -8.84% to 10.83%]). Mortality within 90 days was 12.7% (25/197) in the tenecteplase before EVT group and 14.2% (27/190) in the EVT alone group. Symptomatic intracranial hemorrhage within 36 hours was 5.1% (10/197) and 2.6% (5/190), respectively. CONCLUSIONS AND RELEVANCE: In patients presenting to EVT-capable centers 4.5 to 24 hours after stroke onset with proximal MCA occlusion, intravenous tenecteplase before EVT did not improve clinical outcomes vs EVT alone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06221371.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Xiong Y, Che F, Wang H, et al. Intravenous Tenecteplase Prior to Endovascular Treatment for Ischemic Stroke at 4.5 to 24 Hours: The TNK-PLUS Randomized Clinical Trial. JAMA. 2026. PMID: 42099212. doi:10.1001/jama.2026.4292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。